USE OF A FIXED-DOSE ANTIRETROVIRAL DRUG IN HIV-INFECTED PREGNANT WOMEN
- Autores: Samarina A.V.1,2, Mozaleva O.L.1, Martirosian M.M.1, Skryabneva T.S.1
-
Afiliações:
- Center for Prevention and Control of AIDS and Communicable Diseases
- Academician I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
- Edição: Volume 12, Nº 2 (2022)
- Páginas: 87-94
- Seção: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/287939
- DOI: https://doi.org/10.18565/epidem.2022.12.2.87-94
- ID: 287939
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Objective. To evaluate the efficiency and safety of using a fixed-dose combination (RPV/TDF/FTC) drug during pregnancy. Subjects and methods. This was a retrospective and prospective observational study of RPV/TDF/FTC (Eviplera) used in pregnant women. Forty-three patients whose pregnancy ended in childbirth in 2015 to 2021 were followed up. Results. More than half of the pregnant women had an experience of HIV infection for more than 10 years; this pregnancy was consecutive in 86%, whileprimiparity was in more than two-thirds. The use of antiretroviral therapy (ART) lasted 9.4±0.9 (2-13) years; that of eviplera averaged 3.7 ± 0.7 years. During the RPV/TDF/FTC treatment, all the women had normal CD4+ lymphocyte counts (679.2±28.0 cells/pi) in the first trimester of pregnancy and 755.95 ± 38.6 cells/pl before delivery. In all the women, the level of HIV RNA was <40 copies/mL in the first trimester and at 34-36 weeks’ gestation. There were neither complaints associated with the intake of antiretroviral drugs, nor side effects or adverse events. A term delivery occurred in 9 out of 10patients; the mean gestational age was 38.7±0.3 weeks at the time of delivery. In 80% of the women, their pregnancy ended in childbirth through the birth canal; indications for operative delivery were associated with obstetric pathology in all the cases. None of the newborns was found to have congenital malformations. There were no cases of perinatal HIV infection. Conclusion. The prescription of RPV/TDF/FTC before pregnancy ensured stable suppression of viremia by the time of pregnancy diagnosis, no side effects or adverse events, as well as high adherence to treatment during pregnancy. The safety and efficacy of RPV/TDF/FTC were confirmed by the absence of congenital malformations in newborns and cases of perinatal infection.
Texto integral
Sobre autores
Anna Samarina
Center for Prevention and Control of AIDS and Communicable Diseases; Academician I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Email: avsamarina@mail.ru
MD, Associate Professor, Professor, Department of Social Infections and Phthisiopulmology Saint Petersburg, Russia
Olga Mozaleva
Center for Prevention and Control of AIDS and Communicable Diseases
Email: mozaleva.o@yandex.ru
Obstetrician/Gynecologist, Department of Maternal and Infant Care Saint Petersburg, Russia
Margarita Martirosian
Center for Prevention and Control of AIDS and Communicable Diseases
Email: martirosianmm@mail.ru
Cand. Med. Sci., Obstetrician/ Gynecologist, Department of Maternal and Infant Care Saint Petersburg, Russia
Tatiana Skryabneva
Center for Prevention and Control of AIDS and Communicable Diseases
Email: skryabneva.tanya@mail.ru
Obstetrician/Gynecologist, Department of Maternal and Infant Care Saint Petersburg, Russia
Bibliografia
- Покровский В.В., Ладная Н.Н., Соколова Е.В., Буравцова Е.В. ВИЧ-инфекция. Информационный бюллетень № 43. М: 2018. 55 с
- Ладная Н.Н., Покровский В.В., Дементьева Л.А., Соколова Е.В. ВИЧ-инфекция в Российской Федерации в 2019 году. Материалы Международной научно-практической конференции «Актуальные вопросы ВИЧ-инфекции. охрана здоровья матери и ребенка». СПб: Человек и его здоровье, 2020: 3-9
- Справка по ВИЧ-инфекции в России на 31 декабря 2020 г. http://www.hivrussia.info/wp-content/uploads/2020/07/15
- Покровский В.В. Лекции по ВИЧ-инфекции. Второе изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2018. 848 с
- Самарина А.В., Мозалева О.Л. Социальнодемографические и эпидемиологические характеристики ВИЧ-инфицированных беременных женщин в Санкт-Петербурге как фактор риска перинатальной передачи ВИЧ. ВИЧ-инфекция и иммуносупрессии 2019; 11(3): 7-15. https://doi.org/10.22328/2077-9828-2019-11-3-7-15
- Латышева И.Б., Воронин Е.Е. ВИЧ-инфекция у женщин и детей в Российской Федерации. Материалы научнопрактической конференции «Актуальные вопросы ВИЧ-инфекции. Охрана здоровья матери и ребенка». СПб: Человек и его здоровье, 2020: 9-11
- ВИЧ-инфекция у взрослых. Клинические рекомендации. Национальная ассоциация специалистов по профилактике, диагностике и лечению ВИЧ-инфекции. М., 2020. 136 c
- Department of Health and Human Services. Recommendations for Use of Antiretroviral Drugs in PregnantHIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, 2016. http://aidsinfo.nih/gov/guidelines
- World Health Organization, Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. July 2016. 180 p. http://www.who.int/hiv
- Food and Drug Administration. http://www.accessdata.fda.gov
- Hoffman C., Rockstroh J. (eds.). HIV 2014/2015. Hamburg: Medizin Fokus, 2014. 924 p. https://www.hivbook.com/
- Воронин Е.Е., Афонина Л.Ю., Латышева И.Б., Розенберг В.Я., Фомин Ю.А. (ред.). Клинические рекомендации. ВИЧ-инфекция: Профилактика перинатальной передачи вируса иммунодефицита человека. М.: МЗ РФ, 2017.
- European Guidelines for Treatment of HIV-Positive Adults in Europe. Edition 11.0. European AIDS Clinical Society (EACS). http://www.eacsociety.org/guidelines/eacs-guidelines/ eacsguidelines.html
- Carter A.J. Bourgeois S., O’Brien N., Abelsohn K., Tharao W., Greene S. Women-specific HIV/AIDS services: identifying and defining the components of holistic service delivery for women living with HIV/AIDS. J.Int. AIDS Soc. 2013; 16 (1): 17433. doi: 10.7448/IAS.16.1.17433.
- The Antiretroviral Pregnancy Registry Steering Committee. The Antiretroviral Pregnancy Registry International interim report for 1 January 1989 through 31 Jan 2021 (Issued: June 2021 / Expiration: 6 months after issue). http://www.apregistry.com/forms/interim_report.pdf.20201
- Беляков Н.А., Рахманина Н.Ю., Рахманина А.Г. (ред.). Женщина, ребенок и ВИЧ. 2-е изд. СПб.: Балтийский медицинский образовательный центр, 2012. 600 c
- Самарина А.В., Гусев Д.А., Ястребова Е.Б., Мозалева О.Л. Современные аспекты профилактики перинатальной передачи ВИЧ в Санкт-Петербурге. Журнал инфектологии 2019; 11(1): 58-64. https://doi.org/10.22625/2072-6732-2019-11-1-58-64
- Mandelbrot L., Tubiana R., Le Chenadec J., Dollfus C., Faye A., Pannier E. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin. Infect. Dis. 2015; 61(11): 1715-25. doi: 10.1093/cid/civ578.
- Whiteman M., Kissin D., Samarina A., Akatova N., Marchbanks P.A., Jamieson D.J., Martirosyan M. Determination of contraceptive choice among women with HIV. AIDS 2009; 23(1): 47-54. doi: 10.1097/01. aids.0000363777.76129.b4
- Латышева И.Б., Воронин Е.Е. Мониторинг и оценка мероприятий по профилактике передачи ВИЧ-инфекции от матери ребенку на территории Российской Федерации в 2008-2018 гг. Информационный бюллетень, 2019: 36.
- Delicio A.M., Lajos G.J., Amaral E., Cavichiolli F., Polydoro M., Milanez H. Adverse effects in children exposed to maternal HIV and antiretroviral therapy during pregnancy in Brazil: a cohort study. Reprod. Health. 2018; 15(1): 76. doi: 10.1186/s12978-018-0513-8.
- Uthman O.A., Nachega J.B., Anderson J., Kanters S., Mills E.J., Renaud F., Essajee S., Doherty M.C., Mofenson L.M. Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. Lancet HIV 2017; 4(1): 21-30. doi: 10.1016/S2352-3018(16)30195-3.
- Watts D.H., Williams P.L., Kacanek D., Griner R., Rich K., Hazra R., Mofenson L.M., Mendez H.A.; Pediatric HIV/AIDS Cohort Study.Combination antiretroviral use and preterm birth. J Infect Dis. 2013 Feb 15; 207(4):612-21. doi: 10.1093/ infdis/jis728.
- Hanna N., Bonifacio L., Weinberger B., Reddy P., Murphy S., Romero R., Sharma S. Evidence for interleukin-10-mediated inhibition of cyclo-oxygenase-2 expression and prostaglandin production in preterm human placenta.Am. J. Reprod. Immunol. 2006; 55: 19-27. doi: 10.1111/j.1600-0897.2005.00342.x
Arquivos suplementares
